Pharma Partnerships Vital in Stagnant Alzheimers Disease Treatment Market
Eli Lilly’s recent partnership with AstraZeneca to develop oral beta-secretase cleaving enzyme (BACE) inhibitor AZD3293 for Alzheimer’s Disease (AD) is a positive step forward for this challenging treatment market, says an analyst with research and consulting firm GlobalData.
Kyle Nicholson, PharmD, GlobalData’s Analyst covering Neurology, states that the companies’ joint venture to bring AZD3293 to market is a strategic move that will also encourage more collaboration between large players in an arena with a high drug failure rate.
Nicholson says: “This partnership will enable AstraZeneca and Eli Lilly to combine their expertise in AD and drug development, while sharing the risks and costs associated with potential failure.
“While AstraZeneca is aware of these risks, the company also reports that AZD3293, which is poised to begin registration for trials late this year, could generate annual sales as high as $5 billion if it enters the global market by 2018.”
Nicholson adds that AD has not seen any major advancements in therapy since the approval of cholinesterase inhibitors, donepezil (Eisai/Pfizer’s Aricept), rivastigmine (Novartis’ Exelon), and galantamine (Janssen’s Razadyne), in the 1990s and early 2000s.
Despite significant industry investment, the AD drug market has flat-lined as most existing products are no longer patent-protected. Nevertheless, key opinion leaders interviewed by GlobalData have emphasised that physicians are excited about BACE inhibitors.
Nicholson continues: “Oral BACE inhibitors received greater interest following announcements made by competitors Pfizer, Johnson and Johnson, and Eli Lilly of uninspiring trial results for multiple injectable monoclonal antibody formulations with activity against the enzyme.
“In developing their BACE inhibitor jointly, AstraZeneca and Eli Lilly will now be able to preserve their resources to fund other research and development projects and seek new partnerships. We believe co-operation between major industry players will be crucial in formulating a potentially lucrative new AD-modifying therapy by 2020,” concludes the analyst.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance